RESEARCH ARTICLE
Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies
Maria de Nazaré C Soeiro, Solange Lisboa de Castro*
Article Information
Identifiers and Pagination:
Year: 2011Volume: 5
First Page: 21
Last Page: 30
Publisher ID: TOMCJ-5-21
DOI: 10.2174/1874104501105010021
Article History:
Received Date: 21/1/2010Revision Received Date: 21/4/2010
Acceptance Date: 28/5/2010
Electronic publication date: 9/3/2011
Collection year: 2011

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Chagas disease (CD), caused by the intracellular protozoan Trypanosoma cruzi, is a parasitic illness endemic in Latin America. In the centennial after CD discovery by Carlos Chagas (1909), although it still represents an important public health problem in these affected areas, the existing chemotherapy, based on benznidazole and nifurtimox (both introduced more than four decades ago), is far from being considered ideal due to substantial toxicity, variable effect on different parasite stocks and well-known poor activity on the chronic phase. CD is considered one of the major “neglected” diseases of the world, as commercial incentives are very limited to guarantee investments for developing and discovering novel drugs. In this context, our group has been pursuing, over the last years, the efficacy, selectivity, toxicity, cellular targets and mechanisms of action of new potential anti-T. cruzi candidates screened from an in-house compound library of different research groups in the area of medicinal chemistry. A brief review regarding these studies will be discussed, mainly related to the effect on T. cruzi of (i) diamidines and related compounds, (ii) natural naphthoquinone derivatives, and (iii) megazol derivatives.